The Best Biotechnology Stocks to Invest in Right Now – Best Stocks

Image Source: FreeImages

The global bio-economy is growing at an incredible pace, with plenty of opportunity for investors. The biotech industry in general, and biotech stocks specifically, provide a lot of potential for long-term returns. Biotechnology is the application of biological principles to create new products and services. It has many applications, from agricultural uses to medical research and drug development. As a result, the biotechnology sector has grown strongly as other industries adopt its technologies and invest in related ventures and partnerships.Investors looking to capitalize on this growth need to understand which companies are leading the way. Fortunately, there are several great biotechnology stocks that can offer excellent returns in the coming years. Here are some of the top opportunities currently available:

Global Blood Therapeutics (GBT) is an emerging biotechnology company focused on creating therapies for rare blood diseases.GBTs lead product, Prophage, is a gene therapy designed to treat patients with beta-thalassemia, a rare inherited blood disorder.drug has been granted Orphan Drug Designation by the FDA and designation as a Breakthrough Therapy from the FDAs Oncology Drug Review Committee.GBT has also partnered with Galapagos NV, one of the top gene-therapy companies in the world. The company has a Phase 3 development program for Prophage, with a goal to complete registration in the next few years. With a potential blockbuster drug on the table, GBT has the potential to grow very quickly.

BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on bringing new therapies to patients suffering from rare diseases.BBIO has a robust product pipeline, with several therapies in Phase 1 and 2 clinical trials. The company is also in the pre-clinical development stages of several promising new therapies. BBIOs main product candidates are focused on iron-related disorders, including an iron chelating agent for patients with rare blood diseases.BBIO has partnered with some of the largest companies in the world, including The Medicines Company, Celgene, and Bayer.BBIOs therapies are currently in Phase 2 development and are expected to advance into Phase 3 in the next few years. When these drugs are approved, BBIO will be poised for growth.

SIGA Technologies (SIGA) is a biopharmaceutical company focused on creating vaccines and medicines for infectious diseases.SIGA has a robust product pipeline focused on viral diseases, including respiratory and viral hemorrhagic fever diseases. The company is currently investing in three main products.First is a universal flu vaccine designed to address issues with current flu vaccines. SIGAs universal flu vaccine is administered as a nasal spray, has no adjuvant, and is designed to provide constant immunity to the most common flu strains.Second is an Ebola vaccine designed to treat patients infected with the Ebola virus. The vaccine has been in development since 2003, when the Ebola outbreak in Africa began.Third is a therapeutic vaccine designed to treat dengue fever. The vaccine has completed Phase 1/2 trials and is expected to advance into Phase 3 trials in the next few years.

Ninety (NOVT) is a biotechnology company focused on creating therapies for the eye.NOVT is currently developing a first-in-kind therapy called a corneal scarring therapy that could replace corneal transplants in some patients.The company is expected to advance this product into Phase 3 trials in the next few years. Once the treatment is approved, it could become a huge product for NOVT.While the companys main product remains in development, it is also investing in other eye-related therapies. NOVT has a partnership with Galapagos NV to develop gene therapies for retinal diseases. The company is also developing a novel combination therapy for glaucoma.

Biotechnology is a growing industry that is expected to continue to see strong growth. The sector is also expected to see some strong mergers and acquisitions, providing another avenue for growth.Investors looking for growth in the biotechnology industry can consider investing in any of the top biotechnology stocks above. These companies are all poised for growth over the next several years, and could offer excellent returns for investors.

Image Source: FreeImages

The global economy is growing incredibly, with plenty of opportunities for investors. The biotech industry, in general, and biotech stocks, provide a lot of potential for long-term returns. Biotechnology is the application of biological principles to create new products and services. It has many applications, from agricultural uses to medical research and drug development. As a result, biotechnology has grown strongly as other industries adopt its technologies and invest in related ventures and partnerships. Investors looking to capitalize on this growth need to understand which companies are leading the way. Fortunately, several great biotechnology stocks can offer excellent returns in the coming years. Here are some of the top opportunities currently available:

Global Blood Therapeutics (GBT) is an emerging biotechnology company focused on creating therapies for rare blood diseases.GBTs lead product, Prophage, is a gene therapy designed to treat patients with beta-thalassemia, a rare inherited blood disorder. The drug has been granted Orphan Drug Designation by the FDA and designated as a Breakthrough Therapy by the FDAs Oncology Drug Review Committee.GBT has also partnered with Galapagos NV, one of the top gene-therapy companies in the world. In addition, the company has a Phase 3 development program for Prophage, to complete registration in the next few years. With a potential blockbuster drug on the table, GBT has the potential to grow very quickly.

BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on bringing new therapies to patients suffering from rare diseases.BBIO has a robust product pipeline, with several therapies in Phase 1 and 2 clinical trials. The company is also in the pre-clinical development stages of several promising new therapies. BBIOs main product candidates are focused on iron-related disorders, including an iron chelating agent for patients with rare blood diseases.BBIO has partnered with some of the largest companies in the world, including The Medicines Company, Celgene, and Bayer.BBIOs therapies are currently in Phase 2 development and are expected to advance into Phase 3 in the next few years. When these drugs are approved, BBIO will be poised for growth.

SIGA Technologies (SIGA) is a biopharmaceutical company focused on creating vaccines and medicines for infectious diseases.SIGAs robust product pipeline focused on viral diseases, including respiratory and viral hemorrhagic fever. The company is currently investing in three main products:

The vaccine has completed Phase 1/2 trials and is expected to advance into Phase 3 trials in the next few years.

Ninety (NOVT) is a biotechnology company focused on creating therapies for the eye.NOVT is currently developing a first-in-kind therapy called corneal scarring therapy that could replace corneal transplants in some patients. The company is expected to advance this product into Phase 3 trials in the next few years. Once approved, the treatment could become a huge product for NOVT. While the companys main product remains developing, it is also investing in other eye-related therapies. For example, NOVT partnered with Galapagos NV to develop gene therapies for retinal diseases. In addition, the company is also developing a novel combination therapy for glaucoma.

Biotechnology is a growing industry that is expected to continue to see strong growth. The sector is also expected to see strong mergers and acquisitions, providing another avenue for growth. Investors looking for growth in the biotechnology industry can consider investing in any of the top biotechnology stocks above. These companies are poised for growth over the next several years and could offer excellent returns for investors.

Go here to see the original:
The Best Biotechnology Stocks to Invest in Right Now - Best Stocks